Literature DB >> 10074160

Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties.

T J Chambers1, A Nestorowicz, P W Mason, C M Rice.   

Abstract

A system has been developed for generating chimeric yellow fever/Japanese encephalitis (YF/JE) viruses from cDNA templates encoding the structural proteins prM and E of JE virus within the backbone of a molecular clone of the YF17D strain. Chimeric viruses incorporating the proteins of two JE strains, SA14-14-2 (human vaccine strain) and JE Nakayama (JE-N [virulent mouse brain-passaged strain]), were studied in cell culture and laboratory mice. The JE envelope protein (E) retained antigenic and biological properties when expressed with its prM protein together with the YF capsid; however, viable chimeric viruses incorporating the entire JE structural region (C-prM-E) could not be obtained. YF/JE(prM-E) chimeric viruses grew efficiently in cells of vertebrate or mosquito origin compared to the parental viruses. The YF/JE SA14-14-2 virus was unable to kill young adult mice by intracerebral challenge, even at doses of 10(6) PFU. In contrast, the YF/JE-N virus was neurovirulent, but the phenotype resembled parental YF virus rather than JE-N. Ten predicted amino acid differences distinguish the JE E proteins of the two chimeric viruses, therefore implicating one or more residues as virus-specific determinants of mouse neurovirulence in this chimeric system. This study indicates the feasibility of expressing protective antigens of JE virus in the context of a live, attenuated flavivirus vaccine strain (YF17D) and also establishes a genetic system for investigating the molecular basis for neurovirulence determinants encoded within the JE E protein.

Entities:  

Mesh:

Year:  1999        PMID: 10074160      PMCID: PMC104070     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

Review 1.  Flavivirus genome organization, expression, and replication.

Authors:  T J Chambers; C S Hahn; R Galler; C M Rice
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

2.  Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera.

Authors:  C H Calisher; N Karabatsos; J M Dalrymple; R E Shope; J S Porterfield; E G Westaway; W E Brandt
Journal:  J Gen Virol       Date:  1989-01       Impact factor: 3.891

3.  Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences.

Authors:  C S Hahn; Y S Hahn; C M Rice; E Lee; L Dalgarno; E G Strauss; J H Strauss
Journal:  J Mol Biol       Date:  1987-11-05       Impact factor: 5.469

4.  Production of yellow fever virus proteins in infected cells: identification of discrete polyprotein species and analysis of cleavage kinetics using region-specific polyclonal antisera.

Authors:  T J Chambers; D W McCourt; C M Rice
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

5.  Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein.

Authors:  J J Schlesinger; M W Brandriss; T P Monath
Journal:  Virology       Date:  1983-02       Impact factor: 3.616

6.  Partial nucleotide sequence of the Japanese encephalitis virus genome.

Authors:  P C McAda; P W Mason; C S Schmaljohn; J M Dalrymple; T L Mason; M J Fournier
Journal:  Virology       Date:  1987-06       Impact factor: 3.616

7.  Subgenomic replicons of the flavivirus Kunjin: construction and applications.

Authors:  A A Khromykh; E G Westaway
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use.

Authors:  K H Eckels; Y X Yu; D R Dubois; N J Marchette; D W Trent; A J Johnson
Journal:  Vaccine       Date:  1988-12       Impact factor: 3.641

9.  Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2.

Authors:  S Nitayaphan; J A Grant; G J Chang; D W Trent
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

10.  Maturation of Japanese encephalitis virus glycoproteins produced by infected mammalian and mosquito cells.

Authors:  P W Mason
Journal:  Virology       Date:  1989-04       Impact factor: 3.616

View more
  85 in total

1.  Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response.

Authors:  R G van Der Most; K Murali-Krishna; R Ahmed; J H Strauss
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Attenuation of Murray Valley encephalitis virus by site-directed mutagenesis of the hinge and putative receptor-binding regions of the envelope protein.

Authors:  R J Hurrelbrink; P C McMinn
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses.

Authors:  Rekha Singh; Alan L Rothman; James Potts; Farshad Guirakhoo; Francis A Ennis; Sharone Green
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

4.  High fidelity of yellow fever virus RNA polymerase.

Authors:  Konstantin V Pugachev; Farshad Guirakhoo; Simeon W Ocran; Fred Mitchell; Megan Parsons; Caroline Penal; Soheila Girakhoo; Svetlana O Pougatcheva; Juan Arroyo; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Evaluation of three commercially available Japanese encephalitis virus IgM enzyme-linked immunosorbent assays.

Authors:  Jaimie S Robinson; David Featherstone; Ravi Vasanthapuram; Brad J Biggerstaff; Anita Desai; Nalini Ramamurty; Anwarul Haque Chowdhury; Hardeep S Sandhu; Kathleen F Cavallaro; Barbara W Johnson
Journal:  Am J Trop Med Hyg       Date:  2010-11       Impact factor: 2.345

6.  Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3.

Authors:  S Butrapet; C Y Huang; D J Pierro; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

Authors:  C Y Huang; S Butrapet; D J Pierro; G J Chang; A R Hunt; N Bhamarapravati; D J Gubler; R M Kinney
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 8.  Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.

Authors:  Xing Li; Shu-Juan Ma; Xie Liu; Li-Na Jiang; Jun-Hua Zhou; Yi-Quan Xiong; Hong Ding; Qing Chen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

10.  Neuroadapted yellow fever virus 17D: genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone.

Authors:  T J Chambers; M Nickells
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.